September 20, 2006
To: |
IC Directors |
From: |
Director, Executive Secretariat |
Subject: |
IC Directors' Meeting
Highlights — August 24, 2006 |
Discussion Items
I. Genes and Environment Initiative Update
Dr. Collins began with an overview of the Genes and Environment Initiative
(GEI). He reminded all that this initiative was proposed in the President’s
budget for FY07 and its goal is to accelerate understanding of genetic
and environmental contributions to health and disease. The two components
of the initiative are genotyping of case-control studies of common disease
(identifying genetic variants) and the development of innovative technologies
and biomarkers to measure environmental exposures, diet, physical activity,
psychosocial stress, and addictive substances.
The implementation and management of the GEI consists of the following:
- Budget requests $26M for the genetic component and $14M for the environmental
component. This will be added to the IC base for FY07 and beyond
- In FY07-FY-10, GEI funds will be committed to a common pool and then
will revert back to ICs in FY11 and beyond
- GEI will be managed by NIH-wide Coordinating Committee
- Funds from common pool will be allocated to IC leading a specific
GEI effort
At this time Dr. Collins provided the names of the GEI Coordinating
Committee and thanked them and the subcommittee members for all their
work so far with this initiative.
He then discussed the steps involved in the flow of investigations from
genome-wide association to clinical translation, provided information
specific to the GWA component, and shared the planned timeline for the
GWA studies.
Dr. Schwartz started by discussing how there needs to be improved specificity
and accuracy with the current tools used to assess environmental exposure.
He expanded on the exposure biology program by describing the links from
personal exposures to biology to disease that include:
- Environmental sensors for point of contact to environment chemicals/biologics,
physical activity, diet, psychosocial stress, and substances of abuse
- Biomarkers for the biological response to environmental agents
- Field deployable biosensors
- Application of biomarkers to the genetic studies in the GEI
They concluded their discussion by explaining the integration of GEI
genetics and exposure biology components. These include the following:
- Genetics Program will prioritize study populations with stored biospecimens,
high-quality environmental exposure data, and evidence for environmental
influences on the disease
- Exposure Biology Program will prioritize exposures that are affected
by genetics while focusing on public health problems
- New biomarkers developed through GEI will be applied to stored specimens
in the genome-wide association studies supported through GEI
Dr. Zerhouni thanked Dr. Collins and Dr. Schwartz and their subcommittees
for bringing to this group.
II. Trans-NIH Policies for Genome-Wide Association Studies
Dr. Nabel acknowledged and thanked all the participants that took part
in the NIH Committee on the GWAS policy. She explained that the guiding
principle for writing this policy is that the greatest public benefit
will be realized if data from GWAS are made available, under terms and
conditions consistent with the informed consent provided by individual
participants, in a timely manner to the largest possible number of investigators.
She shared the 2 major goals of the proposed policy:
- Advance science for the benefit of the public through the creation
of a centralized NIH GWAS data repository
- Facilitate research and medical science to better address the health
needs of people based on their individual genetic information
The four major components of the proposed NIH policy for GWAS address:
- Data sharing procedures
- Data access principles
- Intellectual property
- Protection of research participants
Dr. Nabel went on to describe the particular details of each major component
of the proposed NIH policy for GWAS. She also reviewed some “items about
which we may be hearing about” such as human subject issues for data
sharing, data security and validation, and period of publication exclusivity
for PIs.
She then shared some general questions that need public commentary regarding
the GWAS policy. The proposed timeline includes Phase I: planning (completed);
Phase II: public consultation that includes the 60 day RFI for public
comment and public consultations (e.g., Town Hall and Science meetings);
Phase III: policy development that includes final approvals and final
policy release; and concludes with Phase IV: implementation of the final
policy.
Dr. Zerhouni cautioned the group about unintended consequences and the
need to establish a plan for adapting this complicated process by encouraging
collaboration.
III. CFC
Dr. Tabak, this year’s NIH CFC Coordinator, announced upcoming events
for the CFC campaign. He reminded all that last year’s campaign raised
over $2 million and expressed gratitude for the generosity of the NIH
community. The main kick-off event this year is the CFC free throw competition.
This event will follow the October 12, 2006 IC Directors meeting.
Dr. Tabak reviewed the rules for the free throw competition and invited
everyone’s participation.
Ann Brewer
cc: OD Senior Staff
This page was last reviewed on
March 3, 2010
.